vs
Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Caesarstone Ltd. is the larger business by last-quarter revenue ($94.4M vs $92.9M, roughly 1.0× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs -93.1%, a 118.1% gap on every dollar of revenue. Vericel Corp produced more free cash flow last quarter ($12.8M vs $-47.1M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -57.8%).
Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CSTE vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.4M | $92.9M |
| Net Profit | $-87.9M | $23.2M |
| Gross Margin | 15.5% | 78.7% |
| Operating Margin | -87.2% | 24.1% |
| Net Margin | -93.1% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $-2.55 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $94.4M | $92.9M | ||
| Q3 25 | $345.4M | $67.5M | ||
| Q2 25 | $237.7M | $63.2M | ||
| Q1 25 | — | $52.6M | ||
| Q4 24 | — | $75.4M | ||
| Q3 24 | $436.7M | $57.9M | ||
| Q2 24 | $294.3M | $52.7M | ||
| Q1 24 | $150.6M | $51.3M |
| Q4 25 | $-87.9M | $23.2M | ||
| Q3 25 | $-18.5M | $5.1M | ||
| Q2 25 | $-14.3M | $-553.0K | ||
| Q1 25 | — | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $-57.4M | $-901.0K | ||
| Q2 24 | $-56.6M | $-4.7M | ||
| Q1 24 | $-3.9M | $-3.9M |
| Q4 25 | 15.5% | 78.7% | ||
| Q3 25 | 22.5% | 73.5% | ||
| Q2 25 | 23.7% | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | 15.7% | 71.9% | ||
| Q2 24 | 14.1% | 69.5% | ||
| Q1 24 | 19.7% | 68.9% |
| Q4 25 | -87.2% | 24.1% | ||
| Q3 25 | -5.5% | 5.1% | ||
| Q2 25 | -6.2% | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | -12.6% | -4.3% | ||
| Q2 24 | -18.0% | -11.5% | ||
| Q1 24 | -3.9% | -10.7% |
| Q4 25 | -93.1% | 25.0% | ||
| Q3 25 | -5.4% | 7.5% | ||
| Q2 25 | -6.0% | -0.9% | ||
| Q1 25 | — | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | -13.1% | -1.6% | ||
| Q2 24 | -19.2% | -8.9% | ||
| Q1 24 | -2.6% | -7.5% |
| Q4 25 | $-2.55 | $0.46 | ||
| Q3 25 | $-0.54 | $0.10 | ||
| Q2 25 | $-0.41 | $-0.01 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $-1.67 | $-0.02 | ||
| Q2 24 | $-1.64 | $-0.10 | ||
| Q1 24 | $-0.11 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.2M | $354.6M |
| Total Assets | $398.4M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.4M | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-12.6M | — |
| Q4 25 | $139.2M | $354.6M | ||
| Q3 25 | $271.6M | $321.9M | ||
| Q2 25 | $271.6M | $306.8M | ||
| Q1 25 | — | $295.5M | ||
| Q4 24 | — | $292.0M | ||
| Q3 24 | $315.1M | $257.5M | ||
| Q2 24 | $315.1M | $243.0M | ||
| Q1 24 | $315.1M | $233.9M |
| Q4 25 | $398.4M | $488.0M | ||
| Q3 25 | $549.0M | $453.3M | ||
| Q2 25 | $549.0M | $435.6M | ||
| Q1 25 | — | $424.6M | ||
| Q4 24 | — | $432.7M | ||
| Q3 24 | $579.9M | $390.4M | ||
| Q2 24 | $579.9M | $376.8M | ||
| Q1 24 | $579.9M | $356.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.0M | $15.0M |
| Free Cash FlowOCF − Capex | $-47.1M | $12.8M |
| FCF MarginFCF / Revenue | -49.8% | 13.8% |
| Capex IntensityCapex / Revenue | 9.6% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $38.6M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-38.0M | $15.0M | ||
| Q3 25 | $35.0M | $22.1M | ||
| Q2 25 | $18.7M | $8.2M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | $53.3M | $10.2M | ||
| Q2 24 | $25.1M | $18.5M | ||
| Q1 24 | $7.9M | $7.2M |
| Q4 25 | $-47.1M | $12.8M | ||
| Q3 25 | $26.7M | $19.5M | ||
| Q2 25 | $14.3M | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $44.6M | $-9.2M | ||
| Q2 24 | $20.7M | $1.8M | ||
| Q1 24 | $5.0M | $-6.8M |
| Q4 25 | -49.8% | 13.8% | ||
| Q3 25 | 7.7% | 28.8% | ||
| Q2 25 | 6.0% | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | 10.2% | -15.9% | ||
| Q2 24 | 7.0% | 3.4% | ||
| Q1 24 | 3.3% | -13.3% |
| Q4 25 | 9.6% | 2.4% | ||
| Q3 25 | 2.4% | 3.9% | ||
| Q2 25 | 1.8% | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 2.0% | 33.5% | ||
| Q2 24 | 1.5% | 31.8% | ||
| Q1 24 | 1.9% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
